ArticleCase reports in oncological medicine2026
Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade non-muscle-invasive bladder cancer (NMIBC) with lymphovascular invasion is rare in young adults. We report a 27-year-old male, a heavy hookah smoker, who presented with painless gross hematuria. Cystoscopy revealed a large papillary bladder tumor. Transurethral resection demonstrated high-grade pT1 urothelial carcinoma with lymphovascular invasion and uninvolved muscularis propria. Repeat resection 4 weeks later confirmed no residual malignancy. The patient received six induction doses of intravesical BCG and remains recurrence-free at follow-up. This case illustrates an uncommon presentation of high-risk NMIBC in a young patient and demonstrates an excellent early response to bladder-preserving therapy despite adverse pathological features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.